Bevacizumab治療卵巢癌的新知

The Role of Bevacizumab in Ovarian Cancer

Bevacizumab乃一人類單株抗體，可阻斷血管內皮生長因子作用，抑制新血管生成，乃最早研究治療卵巢癌分子導向的藥物。最新文獻綜合分析，bevacizumab合併化學治療，無論是在首次或復發性卵巢癌的治療，均能有效提升無症狀生存時間和總生存時間。美國藥物食品管理局通過，bevacizumab能用在對鉑靈敏或有抗藥性的卵巢癌治療。Bevacizumab的使用效果佳，但最佳使用劑量、療程、途徑和時間，則尚無定論，需有更大規模的研究加以證實。 Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor, which is the first molecular-targeted agent to be used for the treatment of ovarian cancer. In recent meta-analysis, bevacizumab plus chemotherapy, both the first or second-line therapy improved progression-free survival and overall survival in patients with ovarian cancers. The Food and Drug Administration (FDA) approved the treatment using bevacizumab for both in platinum resistant and sensitive recurrent ovarian cancer. However, despite its widespread use with favorable results, controversy regarding patient selection and the best schedule, dosage, route, and timing of bevacizumab still exists. Therefore, more results of ongoing trials investigating the role of bevacizumab alone or in combination with conventional anti-blastic agents are necessary.